Nokoff Natalie J, DuBose Lyndsey, Bothwell Samantha, Cree Melanie G, Kelsey Megan M, Nadeau Kristen J, Moreau Kerrie L
Division of Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Division of Geriatrics, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
J Endocr Soc. 2025 May 13;9(7):bvaf086. doi: 10.1210/jendso/bvaf086. eCollection 2025 Jul.
Transgender adults taking testosterone have impaired endothelial function, a triggering mechanism for cardiovascular disease. The impact of testosterone with and without gonadotropin-releasing hormone agonists (GnRHa) on endothelial function in transgender adolescents is unknown.
To evaluate the effects of 12 months of testosterone therapy on endothelial function among transgender adolescents and whether the effects differ based on exposure to GnRHa.
Longitudinal, observational study with assessments prior to and after 1 and 12 months of testosterone therapy.
Academic regional referral center.
Nineteen adolescents with a female sex (8 receiving GnRHa, 11 not receiving GnRHa).
Clinically prescribed testosterone.
Endothelial function assessed by brachial artery flow mediated dilation (FMD) at baseline and after 1 and 12 months testosterone therapy. Differences between groups were assessed at baseline by -test and over time with a linear regression model with a time*group interaction.
FMD was lower in GnRHa + compared to GnRHa- individuals at baseline (7.9 ± 2.5% vs 10.9 ± 2.9%, = .029) and after 1 month ( = .042) of testosterone therapy. After 12 months of testosterone, FMD was similar between groups: 9.9 ± 4.2% for GnRHa + and 9.8 ± 2.8% for GnRHa- ( = .965). There was a significant interaction in the linear regression model for FMD ( = .030) with an increase in FMD for GnRHa + individuals and a decrease in FMD for GnRHa- individuals after 12 months of testosterone.
Prior to testosterone therapy, GnRHa + individuals had lower endothelial function compared to GnRHa- individuals. The effects of testosterone on endothelial function were modulated by GnRHa status.
服用睾酮的成年跨性别者存在内皮功能受损的情况，这是心血管疾病的一种触发机制。睾酮联合或不联合促性腺激素释放激素激动剂（GnRHa）对跨性别青少年内皮功能的影响尚不清楚。
评估12个月睾酮治疗对跨性别青少年内皮功能的影响，以及这些影响是否因GnRHa的使用情况而有所不同。
纵向观察性研究，在睾酮治疗前、治疗1个月和12个月后进行评估。
学术性区域转诊中心。
19名女性青少年（8名接受GnRHa治疗，11名未接受GnRHa治疗）。
临床规定的睾酮。
在基线、睾酮治疗1个月和12个月后，通过肱动脉血流介导的扩张（FMD）评估内皮功能。组间差异在基线时通过t检验进行评估，随着时间的推移，使用带有时间*组交互作用的线性回归模型进行评估。
在基线时（7.9±2.5%对10.9±2.9%，P=.029）以及睾酮治疗1个月后（P=.042），接受GnRHa治疗的个体的FMD低于未接受GnRHa治疗的个体。睾酮治疗12个月后，两组之间的FMD相似：接受GnRHa治疗的个体为9.9±4.2%，未接受GnRHa治疗的个体为9.8±2.8%（P=.965）。FMD的线性回归模型存在显著交互作用（P=.030），睾酮治疗12个月后，接受GnRHa治疗的个体FMD增加，未接受GnRHa治疗的个体FMD减少。
在睾酮治疗前，接受GnRHa治疗的个体的内皮功能低于未接受GnRHa治疗的个体。睾酮对内皮功能的影响受GnRHa使用情况的调节。
